AIDS and Behavior

, Volume 8, Issue 2, pp 141–150 | Cite as

Factors Influencing Medication Adherence Beliefs and Self-Efficacy in Persons Naive to Antiretroviral Therapy: A Multicenter, Cross-Sectional Study

  • Nancy R. Reynolds
  • Marcia A. Testa
  • Linda G. Marc
  • Margaret A. Chesney
  • Judith L. Neidig
  • Scott R. Smith
  • Stefano Vella
  • Gregory K. Robbins
  • Protocol Teams of ACTG 384, ACTG 731, and A5031s


It is widely recognized that adherence to antiretroviral therapy is critical to long-term treatment success, yet rates of adherence to antiretroviral medications are frequently subtherapeutic. Beliefs about antiretroviral therapy and psychosocial characteristics of HIV-positive persons naive to therapy may influence early experience with antiretroviral medication adherence and therefore could be important when designing programs to improve adherence to antiretroviral therapy. As part of a multicenter AIDS Clinical Trial Group (ACTG 384) study, 980 antiretroviral-naive subjects (82% male, 47% White, median age 36 years, and median CD4 cell count 278 cells/mm3) completed a self-administered questionnaire prior to random treatment assignment of initial antiretroviral medications. Measures of symptom distress, general health and well-being, and personal and situational factors including demographic characteristics, social support, self-efficacy, depression, stress, and current adherence to (nonantiretroviral) medications were recorded. Associations among variables were explored using correlation and regression analyses. Beliefs about the importance of antiretroviral adherence and ability to take antiretroviral medications as directed (adherence self-efficacy) were generally positive. Fifty-six percent of the participants were “extremely sure” of their ability to take all medications as directed and 48% were “extremely sure” that antiretroviral nonadherence would cause resistance, but only 37% were as sure that antiretroviral therapy would benefit their health. Less-positive beliefs about antiretroviral therapy adherence were associated with greater stress, depression, and symptom distress. More-positive beliefs about antiretroviral therapy adherence were associated with better scores on health perception, functional health, social–emotional–cognitive function, social support, role function, younger age, and higher education (r values = 0.09–0.24, all p < .001). Among the subset of 325 participants reporting current use of medications (nonantiretrovirals) during the prior month, depression was the strongest correlate of nonadherence (r = 0.33, p < .001). The most common reasons for nonadherence to the medications were “simply forgot” (33%), “away from home” (27%), and “busy” (26%). In conclusion, in a large, multicenter survey, personal and situational factors, such as depression, stress, and lower education, were associated with less certainty about the potential for antiretroviral therapy effectiveness and one's perceived ability to adhere to therapy. Findings from these analyses suggest a role for baseline screening for adherence predictors and focused interventions to address modifiable factors placing persons at high risk for poor adherence prior to antiretroviral treatment initiation


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., Bamberger, J. D., Chesney, M. A., and Moss, A. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14, 357-366.Google Scholar
  2. Bangsberg, D. R., Hecht, F. M., Clague, H., Charlebois, E. D., Ciccarone, D., Chesney, M., and Moss, A. (2002). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26, 435-442.Google Scholar
  3. Becker, M. H. (1974). The health belief model and personal health behavior. Health Education Monographs, 2, 324-508.Google Scholar
  4. Becker, M. H. (1988). AIDS and behavior change. Public Health Reviews, 16, 1-11.Google Scholar
  5. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., and McAliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19, 124-133.Google Scholar
  6. Chesney, M. A., Morin, M., and Sherr, L. (2000a). Adherence to HIV combination therapy. Social Science and Medicine, 50, 1599-1605.Google Scholar
  7. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., and Wu, A. W. (2000b). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instrument. AIDS Care, 12, 255-266.Google Scholar
  8. Gao, X., Nau, D. P., Rosenbluth, S. A., Scott, V., and Woodward, C. (2000). The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12, 387-398.Google Scholar
  9. Gordillo, V., del Amo, J., Soriano, V., and Gonzalez-Lahoz, J. (1999). Socioeconomic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763-1769.Google Scholar
  10. Haddad, M., Inch, C., Glazier, R. H., Wilkins, A. L., Urbshott, G., Bayoumi, A., and Rourke, S. (2002). Patient support and education for promoting adherence to highly active anitiretroviral therapy for HIV/AIDS. The Cochrane Library, 4, Oxford: Update Software.Google Scholar
  11. Ickovics, J. R., and Meade, C. S. (2002). Adherence to HAART among patients with HIV: Breakthroughs and barriers, AIDS Care, 14, 309-318.Google Scholar
  12. Janz, N. K., and Becker, M. H. (1984). The health belief model: A decade later. Health Education Quarterly, 11, 1-47.Google Scholar
  13. Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., Weissman, S., Neidig, J., Marcus, C., Chesney, M., Cohn, S. E., and Wu, A. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54, S77-S90.Google Scholar
  14. Karon, J. M., Fleming, P. L., Steketee, R. W., and De Cock, K. M. (2001). HIV in the United States at the turn of the century. American Journal of Public Health, 91, 1060-1068.Google Scholar
  15. Kind, P., Dolan, P., Gudewx, C., and Williams, A. (1998). Variations in population health status: Results from a United Kingdom national questionnaire survey. British Medical Journal, 316, 737-741.Google Scholar
  16. Lucas, G. M., Gebo, K. A., Chaisson, R. E., and Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16, 767-774.Google Scholar
  17. Mannheimer, S., Friedland, G., Matts, J., Child, C., and Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115-1121.Google Scholar
  18. Montgomery, S. B., Joseph, J. G., Becker, M. H., Ostrow, D. G., Kessler, R. C., and Kirscht, J. P. (1989). The health belief model in understanding compliance with preventive recommendation for AIDS: How useful? AIDS Education and Prevention, 1, 303-323.Google Scholar
  19. Murphy, D. A., Wilson, C. M., Durako, S. J., Muenz, L. R., and Belzer, M. (2001a). Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27-40.Google Scholar
  20. Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., Kumar, P. N., Mintz, L., Wallach, F. R., and Nemo, G. J. (2001b). Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicine, 135, 17-26.Google Scholar
  21. Nieuwkerk, P. Y., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., vab Der Ende, M. E., Schneider, M. M., Schrey, G., Meenhorst, P. L., Sprenger, H. G., Kauffmann, R. H., Jambroes, M., Chesney, M. A., de Wolf, F., and Lange, J. M. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort. Archives of Internal Medicine 161, 1962-1968.Google Scholar
  22. Ostrop, N. J., Hallet, K. A., and Gill, M. J. (2000). Long-term patient adherence to antiretroviral therapy. Annals of Pharmacotherapy, 34, 703-709.Google Scholar
  23. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuher, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-860.Google Scholar
  24. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., and Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, Annals of Internal Medicine, 133, 21-30.Google Scholar
  25. Radloff, L. S. (1977) The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385-401.Google Scholar
  26. Reynolds, N. R., Testa, M. A., Su, M., Chesney, M. A., and Robbins, G. K. for the Protocol Teams of ACTG 384. (July, 2003). Baseline predictors of adherence and regimen failure in treatment naëve HIV+; subjects (ACTG 384). Presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris.Google Scholar
  27. Safren, S. A., Worth, J. L., Salomon, E., Johnson, W., Mayer, K., and Boswell, S. (2001). Two strategies to increase adherence to HIV antiretroviral medication: Life steps and medication monitoring. Behavioral Research and Therapy 39, 11151-1162.Google Scholar
  28. Schroeder, J. R., Latkin, C. A., Hoover, D. R., Knowlton, A. R., Zenilman, J., Strathdee, S., and Celantano, D. D. (2001). Social factors related to antiretroviral therapy use in injection drug users. AIDS and Behavior, 5, 363-369.Google Scholar
  29. Schuman, P., Ohmit, S. E., Cohen, M., Sacks, H. S., Richardson, J., Young, M., Schoenbaum, E., Rompalo, A., and Gardner, L. (2001). Prescription of and adherence to antiretroviral therapy among women with AIDS. AIDS and Behavior, 5, 371-378.Google Scholar
  30. Smeaton, L. M., DeGruttola, V., Robbins, G. K., and Shafer, R. W. (2001). ACTG (AIDS Clinical Trials Group 384): A strategy trial comparing consecutive treatments for HIV-1. Controlled Clinical Trials, 22, 142-159.Google Scholar
  31. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., and Moatti, J. P. (2002). Adherence to highly active antiretroviral therapy: From a predictive to a dynamic approach. Social Science and Medicine, 54, 1481-1496.Google Scholar
  32. SPSS Inc. (2002). SPSS version 11.5. Chicago: Author.Google Scholar
  33. Volberding, P. (2002). Adherence, resistance and timing: Current issues in the use of new therapies. AIDS Reader, 12, 349-357,368.Google Scholar
  34. Wu, A. W., Rubin, H. R., Matthews, W. C., Ware, J. E., Brysk, L. T., Hardy, W. D., Bozzette, S. A., Spector, S. A., and Richman, D. D. (1991). A health status questionnaire using items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Medical Care, 29, 786-798.Google Scholar
  35. Wu, A. W., Jacobson, D. L., Frick, K. D., Clark, R., Revicki, D. A., Freedberg, K. A., Scott-Lennox, J., and Feinberg, J. (2002). Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Quality of Life Research 11, 273-282.Google Scholar
  36. Yeni, P. G., Hammer, S. M., Carpenter, C., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S., Richman, D. D., Saag, M. S., Schechter, M., Schooley, R. T., Thompson, M. A., Vella, S., and Volberding, P. A. (2002). Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society--USA Panel. JAMA, 288, 222-235.Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • Nancy R. Reynolds
    • 1
  • Marcia A. Testa
    • 2
  • Linda G. Marc
    • 2
  • Margaret A. Chesney
    • 3
  • Judith L. Neidig
    • 1
  • Scott R. Smith
    • 4
  • Stefano Vella
    • 5
  • Gregory K. Robbins
    • 6
  • Protocol Teams of ACTG 384, ACTG 731, and A5031s
  1. 1.Ohio State UniversityColumbus
  2. 2.Harvard School of Public HealthBoston
  3. 3.University of California, San FranciscoSan Francisco
  4. 4.University of North Carolina, Chapel HillChapel Hill
  5. 5.Istituto Superiore di SanitaRomeItaly
  6. 6.Massachusetts General HospitalBoston

Personalised recommendations